Rothschild & Co Upgrades Abbott Laboratories to Buy from Neutral
On October 2, 2026, Rothschild & Co upgraded their outlook for Abbott Laboratories (NYSE:ABT) (BMV:ABT) from Neutral to Buy.
Abbott Laboratories, based in the United States, is a global healthcare company primarily involved in the development, manufacture, and sale of a broad range of healthcare products. The company operates through four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Key projects of Abbott Laboratories include the development of innovative diagnostic devices, such as rapid testing tools that were pivotal during the COVID-19 pandemic, as well as its continuous work in the cardiology sector, particularly in the manufacturing of life-enhancing vascular devices. The company also focuses on the expansion of its nutritional products line, ensuring growth in both pediatric and adult segments.
Prior to the rating action, the stock closed at $96.69 on October 1, 2026. This price reflects a price change of -4.33% over one week, relative to a baseline close of $101.07 on September 24, 2026. Over a one-month period, the stock experienced a price change of -11.24% from a baseline close of $108.93 on September 1, 2026.
Separately, the current consensus target mean for the stock was $123.39, with a median target of $122.40, as of September 15, 2026. This current consensus target represents an implied change of +27.61%. This compares to a prior consensus target mean of $124.16 on August 28, 2026, reflecting a consensus target revision of -0.62%.
In terms of financial performance, Abbott Laboratories last reported earnings on July 16, 2026. The company reported an actual EPS of 1.31, compared to an estimate of 1.2922, representing an EPS surprise of +1.38%. Actual revenue for the quarter was $12,593,000,000.00, compared to an estimated revenue of $12,626,718,050.00. The company's upcoming earnings date is scheduled for October 21, 2026, before the market open.
In the current recommendation period as of September 1, 2026, the aggregate analyst recommendations consisted of 12 strong buy, 13 buy, and 8 hold ratings. This totals 33 recommendations, representing 75.8% positive and 24.2% hold recommendations. In the prior recommendation period as of August 1, 2026, there were 11 strong buy, 13 buy, and 9 hold ratings, totaling 33 recommendations, representing 72.7% positive and 27.3% hold recommendations. Additionally, TD Cowen reiterated their Buy rating on September 8, 2026, with both the from and to ratings set at Buy.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 2, 2026 | Rothschild & Co | Neutral | Buy | upgrade |
| September 8, 2026 | TD Cowen | Buy | Buy | reiterated |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.